Teva Pharmaceutical Industries - Articles and news items

Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research

Industry news / 16 May 2017 / European Federation of Pharmaceutical Industries and Associations (EFPIA)

The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines

EC approves Teva’s Acute Promyelocytic Leukaemia drug

Industry news / 28 November 2016 / Niamh Louise Marriott, Digital Editor

It is the first time that a form of acute leukaemia can be effectively treated with a regimen that is entirely chemotherapy-free…

Teva’s severe eosinophilic asthma drug Cinqaero wins EU approval

Industry news / 18 August 2016 / Caroline Richards, Editor, European Pharmaceutical Review & Drug Target Review

Cinqaero is a humanised interleukin-5 antagonist monoclonal antibody (IgG4 kappa) for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+